ENTERA BIO IS-0000769 (F:5DT) — Market Cap & Net Worth
Market Cap & Net Worth: ENTERA BIO IS-0000769 (5DT)
ENTERA BIO IS-0000769 (F:5DT) has a market capitalization of $50.93 Million (€43.56 Million) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #21809 globally and #1937 in its home market, demonstrating a -2.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ENTERA BIO IS-0000769's stock price €0.95 by its total outstanding shares 45857242 (45.86 Million).
ENTERA BIO IS-0000769 Market Cap History: 2020 to 2026
ENTERA BIO IS-0000769's market capitalization history from 2020 to 2026. Data shows change from $43.96 Million to $50.93 Million (-6.79% CAGR).
ENTERA BIO IS-0000769 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ENTERA BIO IS-0000769's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 5DT by Market Capitalization
Companies near ENTERA BIO IS-0000769 in the global market cap rankings as of May 4, 2026.
Key companies related to ENTERA BIO IS-0000769 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
ENTERA BIO IS-0000769 Historical Marketcap From 2020 to 2026
Between 2020 and today, ENTERA BIO IS-0000769's market cap moved from $43.96 Million to $ 50.93 Million, with a yearly change of -6.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €50.93 Million | -36.16% |
| 2025 | €79.77 Million | -26.34% |
| 2024 | €108.30 Million | +322.59% |
| 2023 | €25.63 Million | -20.83% |
| 2022 | €32.37 Million | -76.41% |
| 2021 | €137.25 Million | +212.20% |
| 2020 | €43.96 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of ENTERA BIO IS-0000769 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $50.93 Million USD |
| MoneyControl | $50.93 Million USD |
| MarketWatch | $50.93 Million USD |
| marketcap.company | $50.93 Million USD |
| Reuters | $50.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ENTERA BIO IS-0000769
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial … Read more